全文获取类型
收费全文 | 58065篇 |
免费 | 5477篇 |
国内免费 | 2572篇 |
专业分类
耳鼻咽喉 | 487篇 |
儿科学 | 1044篇 |
妇产科学 | 988篇 |
基础医学 | 5331篇 |
口腔科学 | 750篇 |
临床医学 | 6184篇 |
内科学 | 10800篇 |
皮肤病学 | 825篇 |
神经病学 | 3660篇 |
特种医学 | 1762篇 |
外国民族医学 | 14篇 |
外科学 | 8505篇 |
综合类 | 10037篇 |
现状与发展 | 8篇 |
预防医学 | 1777篇 |
眼科学 | 2737篇 |
药学 | 5648篇 |
19篇 | |
中国医学 | 2755篇 |
肿瘤学 | 2783篇 |
出版年
2024年 | 56篇 |
2023年 | 910篇 |
2022年 | 1279篇 |
2021年 | 2227篇 |
2020年 | 2210篇 |
2019年 | 2027篇 |
2018年 | 2041篇 |
2017年 | 2108篇 |
2016年 | 2177篇 |
2015年 | 2269篇 |
2014年 | 3863篇 |
2013年 | 4213篇 |
2012年 | 3426篇 |
2011年 | 3813篇 |
2010年 | 3266篇 |
2009年 | 3305篇 |
2008年 | 3330篇 |
2007年 | 3305篇 |
2006年 | 3129篇 |
2005年 | 2775篇 |
2004年 | 2366篇 |
2003年 | 2014篇 |
2002年 | 1662篇 |
2001年 | 1354篇 |
2000年 | 1113篇 |
1999年 | 833篇 |
1998年 | 613篇 |
1997年 | 539篇 |
1996年 | 502篇 |
1995年 | 434篇 |
1994年 | 384篇 |
1993年 | 298篇 |
1992年 | 284篇 |
1991年 | 259篇 |
1990年 | 199篇 |
1989年 | 178篇 |
1988年 | 159篇 |
1987年 | 149篇 |
1986年 | 137篇 |
1985年 | 148篇 |
1984年 | 143篇 |
1983年 | 94篇 |
1982年 | 100篇 |
1981年 | 117篇 |
1980年 | 86篇 |
1979年 | 61篇 |
1978年 | 51篇 |
1977年 | 31篇 |
1976年 | 24篇 |
1975年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
《Transfusion and apheresis science》2022,61(1):103368
The endothelium is a single-layered structure that responds to physical and chemical signals with various factors it synthesizes. In the early days of its discovery, as the inner wall of the vessels, the endothelium was thought to be a simple barrier that lays on the surface. Over time it is discovered that endothelium maintains body homeostasis with the molecules it synthesizes, despite its simple single-layer structure. It has been accepted as an important organ that contributes to the maintenance of vascular tone, cell adhesion, inflammation, vascular permeability and coagulation. Any imbalance in these physiological and pathological events causes endothelial dysfunction. This can cause many diseases such as atherosclerosis, hypertension, diabetes, or it can occur because of these. Endothelial related disorders may also complicate hematopoietic stem cell transplantation (HSCT), which is used to treat various hematologic and neoplastic diseases. These life-threatening complications include graft-versus-host disease, hepatic veno-occlussive disease, transplant-associated thrombotic microangiopathy and diffuse alveolar hemorrhage. They share a similar pathophysiology involving endothelial cells with different clinical presentations. Therefore, current researche on the issue is putting the endothelium under the spotlight for novel markers and treatment options that should be used to monitor or treat at least some of these complications following HSCT. 相似文献
5.
6.
7.
《Journal of vascular and interventional radiology : JVIR》2022,33(9):1034-1044.e29
PurposeTo assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.Materials and MethodsThe VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7–21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging.ResultsEight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441–404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%–100%). There were no significant changes in perfusion imaging parameters after TACE.ConclusionsBTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies. 相似文献
8.
《Saudi Pharmaceutical Journal》2022,30(5):595-604
Anthrax is a zoonotic infection caused by the gram-positive, aerobic, spore-forming bacterium Bacillus anthracis. Depending on the origin of the infection, serious health problems or mortality is possible. The virulence of B. anthracis is reliant on three pathogenic factors, which are secreted upon infection: protective antigen (PA), lethal factor (LF), and edema factor (EF). Systemic illness results from LF and EF entering cells through the formation of a complex with the heptameric form of PA, bound to the membrane of infected cells through its receptor. The currently available anthrax vaccines have multiple drawbacks, and recombinant PA is considered a promising second-generation vaccine candidate. However, the inherent chemical instability of PA through Asn deamidation at multiple sites prevents its use after long-term storage owing to loss of potency. Moreover, there is a distinct possibility of B. anthracis being used as a bioweapon; thus, the developed vaccine should remain efficacious and stable over the long-term. Second-generation anthrax vaccines with appropriate adjuvant formulations for enhanced immunogenicity and safety are desired. In this article, using protein engineering approaches, we have reviewed the stabilization of anthrax vaccine candidates that are currently licensed or under preclinical and clinical trials. We have also proposed a formulation to enhance recombinant PA vaccine potency via adjuvant formulation. 相似文献
9.
10.